Cargando…

CTSE Overexpression Is an Adverse Prognostic Factor for Survival among Rectal Cancer Patients Receiving CCRT

The introduction of preoperative concurrent chemoradiotherapy (CCRT) increases the rate of anal preservation and allows tumor downstaging for clinical stage T3/T4 or node-positive rectal cancer patients. However, there is no precise predictive tool to verify the presence of residual tumor apart from...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Chia-Lin, Chen, Tzu-Ju, Tian, Yu-Feng, Chan, Ti-Chun, Yeh, Cheng-Fa, Li, Wan-Shan, Tsai, Hsin-Hwa, Li, Chien-Feng, Lai, Hong-Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304221/
https://www.ncbi.nlm.nih.gov/pubmed/34357018
http://dx.doi.org/10.3390/life11070646
_version_ 1783727281553801216
author Chou, Chia-Lin
Chen, Tzu-Ju
Tian, Yu-Feng
Chan, Ti-Chun
Yeh, Cheng-Fa
Li, Wan-Shan
Tsai, Hsin-Hwa
Li, Chien-Feng
Lai, Hong-Yue
author_facet Chou, Chia-Lin
Chen, Tzu-Ju
Tian, Yu-Feng
Chan, Ti-Chun
Yeh, Cheng-Fa
Li, Wan-Shan
Tsai, Hsin-Hwa
Li, Chien-Feng
Lai, Hong-Yue
author_sort Chou, Chia-Lin
collection PubMed
description The introduction of preoperative concurrent chemoradiotherapy (CCRT) increases the rate of anal preservation and allows tumor downstaging for clinical stage T3/T4 or node-positive rectal cancer patients. However, there is no precise predictive tool to verify the presence of residual tumor apart from surgical resection. The gastrointestinal (GI) tract not only digests nutrients but also coordinates immune responses. As the outermost layer of the GI tract, mucus plays a key role in mediating the interaction between the digestive and immune systems, and aberrant mucus mesh formation may cause chemoresistance by impeding drug delivery. However, the correlations among digestion-related genes, mucin synthesis, and chemoresistance remain poorly understood. In the present study, we evaluated genes related to digestion (GO: 0007586) and identified cathepsin E (CTSE), which is involved in immune regulation, as the most significantly upregulated gene associated with CCRT resistance in rectal cancer in a public transcriptome dataset (GSE35452). We recovered 172 records of rectal cancer patients receiving CCRT followed by surgical resection from our biobank and evaluated the expression level of CTSE using immunohistochemistry. The results revealed that tumors with CTSE overexpression were significantly correlated with pre-CCRT and post-CCRT positive nodal status (both p < 0.001), advanced pre-CCRT and post-CCRT tumor status (p < 0.001 and p = 0.002), perineural invasion (p = 0.023), vascular invasion (p < 0.001), and a lesser degree of tumor regression (p = 0.003). At the univariate level, CTSE overexpression was an adverse prognostic factor for all three endpoints: disease-specific survival (DSS), metastasis-free survival (MeFS) (both p < 0.0001), and local recurrence-free survival (LRFS) (p = 0.0001). At the multivariate level, CTSE overexpression remained an independent prognostic factor for poor DSS, MeFS (both p = 0.005), and LRFS (p = 0.019). Through bioinformatics analysis, we speculated that CTSE overexpression may confer CCRT resistance by forming a defensive mucous barrier. Taken together, these results suggest that CTSE overexpression is related to CCRT resistance and inferior survival in rectal cancer patients, highlighting the potential predictive and prognostic value of CTSE expression.
format Online
Article
Text
id pubmed-8304221
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83042212021-07-25 CTSE Overexpression Is an Adverse Prognostic Factor for Survival among Rectal Cancer Patients Receiving CCRT Chou, Chia-Lin Chen, Tzu-Ju Tian, Yu-Feng Chan, Ti-Chun Yeh, Cheng-Fa Li, Wan-Shan Tsai, Hsin-Hwa Li, Chien-Feng Lai, Hong-Yue Life (Basel) Article The introduction of preoperative concurrent chemoradiotherapy (CCRT) increases the rate of anal preservation and allows tumor downstaging for clinical stage T3/T4 or node-positive rectal cancer patients. However, there is no precise predictive tool to verify the presence of residual tumor apart from surgical resection. The gastrointestinal (GI) tract not only digests nutrients but also coordinates immune responses. As the outermost layer of the GI tract, mucus plays a key role in mediating the interaction between the digestive and immune systems, and aberrant mucus mesh formation may cause chemoresistance by impeding drug delivery. However, the correlations among digestion-related genes, mucin synthesis, and chemoresistance remain poorly understood. In the present study, we evaluated genes related to digestion (GO: 0007586) and identified cathepsin E (CTSE), which is involved in immune regulation, as the most significantly upregulated gene associated with CCRT resistance in rectal cancer in a public transcriptome dataset (GSE35452). We recovered 172 records of rectal cancer patients receiving CCRT followed by surgical resection from our biobank and evaluated the expression level of CTSE using immunohistochemistry. The results revealed that tumors with CTSE overexpression were significantly correlated with pre-CCRT and post-CCRT positive nodal status (both p < 0.001), advanced pre-CCRT and post-CCRT tumor status (p < 0.001 and p = 0.002), perineural invasion (p = 0.023), vascular invasion (p < 0.001), and a lesser degree of tumor regression (p = 0.003). At the univariate level, CTSE overexpression was an adverse prognostic factor for all three endpoints: disease-specific survival (DSS), metastasis-free survival (MeFS) (both p < 0.0001), and local recurrence-free survival (LRFS) (p = 0.0001). At the multivariate level, CTSE overexpression remained an independent prognostic factor for poor DSS, MeFS (both p = 0.005), and LRFS (p = 0.019). Through bioinformatics analysis, we speculated that CTSE overexpression may confer CCRT resistance by forming a defensive mucous barrier. Taken together, these results suggest that CTSE overexpression is related to CCRT resistance and inferior survival in rectal cancer patients, highlighting the potential predictive and prognostic value of CTSE expression. MDPI 2021-07-02 /pmc/articles/PMC8304221/ /pubmed/34357018 http://dx.doi.org/10.3390/life11070646 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chou, Chia-Lin
Chen, Tzu-Ju
Tian, Yu-Feng
Chan, Ti-Chun
Yeh, Cheng-Fa
Li, Wan-Shan
Tsai, Hsin-Hwa
Li, Chien-Feng
Lai, Hong-Yue
CTSE Overexpression Is an Adverse Prognostic Factor for Survival among Rectal Cancer Patients Receiving CCRT
title CTSE Overexpression Is an Adverse Prognostic Factor for Survival among Rectal Cancer Patients Receiving CCRT
title_full CTSE Overexpression Is an Adverse Prognostic Factor for Survival among Rectal Cancer Patients Receiving CCRT
title_fullStr CTSE Overexpression Is an Adverse Prognostic Factor for Survival among Rectal Cancer Patients Receiving CCRT
title_full_unstemmed CTSE Overexpression Is an Adverse Prognostic Factor for Survival among Rectal Cancer Patients Receiving CCRT
title_short CTSE Overexpression Is an Adverse Prognostic Factor for Survival among Rectal Cancer Patients Receiving CCRT
title_sort ctse overexpression is an adverse prognostic factor for survival among rectal cancer patients receiving ccrt
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304221/
https://www.ncbi.nlm.nih.gov/pubmed/34357018
http://dx.doi.org/10.3390/life11070646
work_keys_str_mv AT chouchialin ctseoverexpressionisanadverseprognosticfactorforsurvivalamongrectalcancerpatientsreceivingccrt
AT chentzuju ctseoverexpressionisanadverseprognosticfactorforsurvivalamongrectalcancerpatientsreceivingccrt
AT tianyufeng ctseoverexpressionisanadverseprognosticfactorforsurvivalamongrectalcancerpatientsreceivingccrt
AT chantichun ctseoverexpressionisanadverseprognosticfactorforsurvivalamongrectalcancerpatientsreceivingccrt
AT yehchengfa ctseoverexpressionisanadverseprognosticfactorforsurvivalamongrectalcancerpatientsreceivingccrt
AT liwanshan ctseoverexpressionisanadverseprognosticfactorforsurvivalamongrectalcancerpatientsreceivingccrt
AT tsaihsinhwa ctseoverexpressionisanadverseprognosticfactorforsurvivalamongrectalcancerpatientsreceivingccrt
AT lichienfeng ctseoverexpressionisanadverseprognosticfactorforsurvivalamongrectalcancerpatientsreceivingccrt
AT laihongyue ctseoverexpressionisanadverseprognosticfactorforsurvivalamongrectalcancerpatientsreceivingccrt